Strategies for the Identification of T Cell–Recognized Tumor Antigens in Hematological Malignancies for Improved Graft-versus-Tumor Responses after Allogeneic Blood and Marrow Transplantation  by Zilberberg, Jenny et al.
Biol Blood Marrow Transplant 21 (2015) 1000e1007Biology of Blood and
Marrow Transplantation
journal homepage: www.bbmt.orgReviewsStrategies for the Identiﬁcation of T CelleRecognized
Tumor Antigens in Hematological Malignancies for
Improved Graft-versus-Tumor Responses after
Allogeneic Blood and Marrow TransplantationJenny Zilberberg*, Rena Feinman, Robert Korngold
Research Department and John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New JerseyArticle history:
Received 28 July 2014









Hematological malignancyFinancial disclosure: See Acknowl





1083-8791/ 2015 American Sociea b s t r a c t
Allogeneic blood and marrow transplantation (allo-BMT) is an effective immunotherapeutic treatment that
can provide partial or complete remission for patients with hematological malignancies. Mature donor T cells
in the donor inoculum play a central role in mediating graft-versus-tumor (GVT) responses by destroying
residual tumor cells that persist after conditioning regimens. Alloreactivity towards minor histocompatibility
antigens (miHA), which are varied tissue-related self-peptides presented in the context of major histocom-
patibility complex (MHC) molecules on recipient cells, some of which may be shared on tumor cells, is a
dominant factor for the development of GVT. Potentially, GVT can also be directed to tumor-associated an-
tigens or tumor-speciﬁc antigens that are more speciﬁc to the tumor cells themselves. The full exploitation of
allo-BMT, however, is greatly limited by the development of graft-versus-host disease (GVHD), which is
mediated by the donor T cell response against the miHA expressed in the recipient’s cells of the intestine,
skin, and liver. Because of the signiﬁcance of GVT and GVHD responses in determining the clinical outcome of
patients, miHA and tumor antigens have been intensively studied, and one active immunotherapeutic
approach to separate these two responses has been cancer vaccination after allo-BMT. The combination of
these two strategies has an advantage over vaccination of the patient without allo-BMT because his or her
immune system has already been exposed and rendered unresponsive to the tumor antigens. The condi-
tioning for allo-BMT eliminates the patient’s existing immune system, including regulatory elements, and
provides a more permissive environment for the newly developing donor immune compartment to selec-
tively target the malignant cells. Utilizing recent technological advances, the identities of many human miHA
and tumor antigenic peptides have been deﬁned and are currently being evaluated in clinical and basic
immunological studies for their ability to produce effective T cell responses. The ﬁrst step towards this goal is
the identiﬁcation of targetable tumor antigens. In this review, we will highlight some of the technologies
currently used to identify tumor antigens and anti-tumor T cell clones in hematological malignancies.
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Adoptive T cell therapy in the form of allogeneic blood
andmarrow transplantation (allo-BMT) has proven to be one
of the few curative treatments for a number of drug-resistant
hematological malignancies [1,2]. To date, the gold standard
of immunotherapy used in the treatment of patients with
acute myeloid leukemia (AML), lymphoma, chronic lym-
phocytic leukemia (CLL), chronic myeloid leukemia (CML),edgments on page 1005.
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ty for Blood and Marrow Transplantation.lymphocytes along with, or at some time after, allo-BMT (in
the form of donor lymphocyte infusions) [3]. The broad
donor-derived CD4þ and CD8þ T cell repertoire targeting a
diversity of undeﬁned (allogeneic) tumor antigens is
exploited in this setting [1,3,4].
Allo-BMT permits partial or complete remission in a sig-
niﬁcant percentage of patients. Although mature donor T
cells in the donor inoculum facilitate patient immune
reconstitution and mediate graft-versus-tumor (GVT)
responses by destroying residual tumor cells that persist
after conditioning regimens [5-7], the full exploitation of this
clinical intervention is greatly limited by the development of
graft-versus-host disease (GVHD). This primary complication
of allo-BMT is due to the donor T cell allogeneic response
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may or may not be shared by tumor cells [8-10]. Therefore,
even in a fully major histocompatibility complex (MHC)-
matched (in humans, HLA-matched) transplantation set-
tings, the alloreactivity towards recipient cells is the key
factor for the development of both GVT and GVHD effects.
Unfortunately, the uncoupling of these two events to
improve transplantation outcomes has yet to be achieved in
a consistent and efﬁcient manner. GVT can also be directed to
tumor-speciﬁc target antigens that are not expressed by
normal host tissues. Therefore, to reduce the development of
GVHD and potentiate the GVT response, one active immune
approach in the clinic has been the use of cancer vaccination
after allo-BMT [11]. This combined strategy has an advantage
over mere vaccination of the patient without allo-BMT, for
the immune system of the patient has already been exposed
and, hence, has become unresponsive to the tumor antigens,
whereas the newly developing donor immune compartment
can be educated to selectively target malignant cells. The ﬁrst
step towards this goal is the identiﬁcation of targetable tu-
mor antigens [12,13]. In this review, we will highlight some
of the technologies currently used to identify tumor antigens
and antitumor T cell clones in hematological malignancies.
CLASSIFICATION OF TUMOR ANTIGENS
Tumor antigens are classiﬁed according to their distri-
bution as tumor-speciﬁc antigens (TSA), which are only
expressed by the tumor, or as tumor-associated antigens
(TAA), which can also be found in other normal cell types
[11,13-16]. Unique tumor antigens, on the other hand, are
those of patient-restricted expression whereas shared anti-
gens are commonly present across various samples of the
same histologic subtype of malignancy and on different tu-
mor types, but not in normal tissues, except for testis and
placenta. Although shared antigens constitute an ideal group
to develop broadly applicable cancer vaccines, the identiﬁ-
cation of unique TSA has the potential to develop into highly
effective personalized immunotherapeutic interventions.
Other classiﬁcations that stem from the combinations of
these different types of antigens are as follows.
Unique TSA
These antigens result from somatic point mutations
induced by carcinogens and, therefore, occur in a single tu-
mor of one patient; thus, they represent a bone ﬁde TSA not
capable of being expressed by any normal tissue. Impor-
tantly, unique TSA have the potential to elicit more effective
antitumor vaccine responses than shared antigens because of
their resistance to immunoselection, particularly if the
mutated protein is critical for the preservation of neoplastic
cells. For a thorough review of identiﬁed unique tumor an-
tigens, see Parmiani et al. [14].
Shared TSA
These antigens are expressed in different tumors but not
in healthy tissues. The most prominent antigens among this
group are the cancer-testis family of antigens including
MAGE [17,18], BAGE, LAGE, GAGE, and NY-ESO-1 [19-22],
which in normal tissues are restricted only to the testis and
placenta but can be found in MM, breast, ovarian, and head
and neck cancers [23,24].
Shared TAA
This category of antigens, although not tumor speciﬁc, is
overexpressed in different types of tumors. Examples ofthese antigens are human telomerase reverse transcriptase
[25], survivin [26,27], proteinase-3 [28,29], Wilms tumor
gene-encoded transcription factor-1 (WT1) [30,31], mucin-1
[32], and preferentially expressed antigen of melanoma
(PRAME) [33], which can be found only at very low levels in
healthy tissues, such as the adrenal glands, ovaries, and
endometrium. Shared TAA have been considered as potential
targets for cancer immunotherapy. Arai et al. [34] demon-
strated that CD8þ cytotoxic T cell (CTL) clones speciﬁc for
human telomerase reverse transcriptase peptides exerted
cytotoxicity against leukemia cells in an HLA-A24erestricted
manner, while sparing HLA-A24- leukemia cells or HLA-A24-
normal cells. PRAME is known to contain at least 4 different
HLA-A*0201-restricted epitopes (PRA100e108, PRA142e151,
PRA300e309, and PRA425e433) [35] recognized by CTLs [36].
Reports of PRAME antigen expression range from 47% to 70%
of AML patients [37,38]. Proteinase-3 is also overexpressed in
AML and CML [28,39,40] and WT1 is overtly present in
several different types of leukemia [41]. In fact, WT1 ranked
in the top 20 antigens with suggestive high therapeutic
functionality according to the National Cancer Institute
report on the prioritization of cancer antigens for accelera-
tion of translational research [42]. WT1 is also among the
most advanced targets for AML immunotherapy, as reﬂected
by the relatively large number of WT1-targeted vaccine trials
for AML patients [43]. In those patients, multiple WT1 CTL
epitopes have been recognized as immunogenic (including
WT137e45, WT1126e134, WT1187e195, and WT1235e243) [43].
WT1 was also found to induce WT1-speciﬁc CD4þ helper T
cell immunity in patients with AML through active immu-
nization [44]. Mucin-1, an epithelial mucin present in a
number of solid tumors, can also be found in MM cell lines
and primary tumors [45-49]. For an in-depth review of
tumor antigens recognized by T cells, and in particular
those pertinent to hematological malignancies, see Novellino
et al. [50], Borrello et al. [11], and Anguille et al. [41].
Minor Histocompatibility Antigens (miHA)
In the context of an MHC-matched allo-BMT, allor-
eactive CD8þ and CD4þ donor T cells can also be directed at
noneMHC-encoded polymorphic peptides known as miHA,
presented by both MHC class I and class II molecules
[51,52] on allogeneic host cells. Many of these miHA are
encoded by allelic genes that can differ between patient
and donor because of single nucleotide polymorphisms
(SNPs). The target molecules involved in the GVT response
can be any of the TSA or TAA described above, as well as
tissue- and tumor-speciﬁc miHA. Donor T cells have the
advantage of recognizing all of these target antigens in an
immunologically permissive environment, whereas in the
patient, T cell responses are generated only against TSA and
TAA and are subject to tolerizing mechanisms. Conceptu-
ally, in the allo-BMT setting, all tumor antigens presented
in the context of MHC that are recognized by donor but not
host T cells are miHA.
In 1978, Korngold and Sprent demonstrated that transfer
of bone marrow cells containing T cells into lethally irradi-
ated MHC-matched recipient mice caused GVHD, suggesting
that miHAs were the main target for eliciting this disease
[53]. The use of miHA as tumor targets after allo-BMT derives
from the notion that some of these antigens are exclusively
expressed on normal andmalignant host hematopoietic cells
permitting, hypothetically, the separation of GVT and GVHD
pathological responses [54,55]. In some cases, miHA can also
be considered as TAA in that they may be overexpressed in
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compartment. The contribution of miHA in GVT has been
evaluated mainly by isolating CTL with tumor lytic capability
and studying their effect on normal host hematopoietic cells
or nonhematopoietic ﬁbroblast cells. Later on in this review,
we will discuss work by the present authors using other
technological approaches aimed at identifying and sepa-
rating tumor versus tissue reactive T cell clones using spec-
tratype analysis and T cell receptor (TCR) sequencing.
HA-1 and HA-2 constitute the ﬁrst 2miHA identiﬁed to be
solely expressed on hematopoietic cells [54,56], including
progenitor cells. Both of these antigens have been found to be
expressed in all leukemia and MM cells [57,58]. Subse-
quently, a number of other hematopoietic miHA have been
identiﬁed, including HB-1, an acute B-lymphoblastoid-
leukemia-related antigen [59], and proliferation-associated
nuclear element 1 gene [60,61], a B cell CLLerelated anti-
gen. Although ubiquitous, the ATP-dependent, interferon-
responsive gene (ADIR) is also highly expressed in activated
hematopoietic cells, including MM and various solid tumors
[62]. LRH1, encoded by the P2X5 gene, is hematopoietic
speciﬁc and expressed in leukemic cells and their CD34þ
progenitors [63]. A number of other miHA encoded by
ubiquitously expressed genes appear to be preferentially
expressed in activated hematopoietic cells and malignant
cells (see Table 1 in references [13,64]). A retrospective
analysis on the impact of a panel of 17 immunogenic miHAs
including HA-1, HA-2, HA-8, ATP-dependent, interferon-
responsive, proliferation-associated nuclear element 1,
LRH1, SP110, ECGF, and ACC2, in patients who received a
partial T celledepleted HLA-identical allo-BMT, revealed
that in sibling transplantations, mismatches in one or more
of the studied autosomal-encoded miHA resulted in an
improved relapse-free survival rate, especially in MM
patients [65].
Of note, mismatches in individual miHA, including HA-1,
HA-2, and HA-8, have been associated with increased GVHD
occurrence and lower relapse rates [66], although other
studies could not conﬁrm these results [67]. The adoptive
transfer of miHA-speciﬁc CTLs selected on the basis of
recognition of recipient hematopoietic cells but not skin ﬁ-
broblasts has also unexpectedly been associated with GVHD.
Likewise, in a murine model of BMT, infusion of tumor-
speciﬁc CTLs identiﬁed by CDR3-size spectratype analysis
was shown to induce a signiﬁcant GVT response, but the
same tumor-reactive Vb family, which initially showed no
hematopoietic alloreactivity was ultimately the causal entity
of gut pathology in recipient mice, when administered at
higher dosages [68]. Taken together, the results from these
clinical trials and murine models suggest that responses to
target tissueerelated miHA are complex and may vary not
only amongst different individuals but also between tissue
types.
In 2009, The Translational ResearchWorking Group of the
National Cancer Institute speciﬁed a number of criteria for
determining the suitability of a given tumor antigen for
therapeutic application. The following characteristics were
evaluated and prioritized in descending order to determine
the “ideal” cancer antigen: (1) therapeutic function, (2)
immunogenicity, (3) role of the antigen in oncogenicity, (4)
speciﬁcity, (5) expression level and percent of antigen-
positive cells, (6) stem cell expression, (7) number of
patients with antigen-positive cancers, (8) number of anti-
genic epitopes, and (9) cellular location of antigen expres-
sion. Although there was no assessment of miHA using thisprioritization analysis, it was concluded that none of the 75
tumor antigens studied ﬁt all the criteria of the “ideal” cancer
antigen. Nevertheless, 46 antigens were reported as immu-
nogenic in clinical trials and 20 antigens had suggestive
clinical efﬁcacy in the “therapeutic function” category [42].
Approaches to Identify Tumor Antigens
The characterization of a tumor-speciﬁc CTL epitope from
the humanmelanoma antigen MAGE-1 was reported in 1992
by Boon et al. [17,18]. Since this discovery, a number of
technological advances have led to a great increase in the
number of recognized TAA. The ﬁrst strategy used to identify
tumor antigens was peptide elution. This approach is based
on high-liquid performance chromatography paired with
mass spectrometric sequencing of the miHA peptide eluted
from the cell surface of MHC molecules [62,69-72]. This
technique, despite being very successful, has only yielded
positive results in identifying HLA class Iepresented miHA.
In addition to peptide elution, forward or “T cell-to-anti-
gen”ebased strategy and reverse immunology are two major
strategies that have been recently used in the identiﬁcation
of tumor antigens and CD8þ and CD4þ T cell epitopes con-
tained in these tumor-speciﬁc proteins.
Forward Immunology Methods
Broadly speaking, these methods are characterized by the
isolation of tumor-reactive T cells generated from an autol-
ogous peripheral blood mononuclear cell coculture with
tumor cells or from individuals who underwent trans-
plantation demonstrating a clinical response to donor
lymphocyte infusions after allo-BMT, followed by the sub-
sequent identiﬁcation of the antigens that elicited a T cell
response. For a review of immunogenic scenarios conducive
for the identiﬁcation of tumor antigens in this forward
manner, see Kawakami et al. [73]. Forward immunological
techniques and their variations can be applied to identify
miHA presented in the context of either MHC-I or MHC-II.
After the isolation and expansion of CTLs, these lines can
be used to isolate the tumor-speciﬁc cDNA that encodes the
recognized CTL epitope by screening of cDNA expression li-
braries (Figure 1) derived from the tumor or Epstein-Barr
virus (EBV)-transformed lymphoblastoid cell lines from
members of CEPH families (Jean Dausset-Centre d’Etude du
Polymorphisme Humain [CEPH]; http://www.cephb.fr/en/
cephdb/), followed by genetic linkage analysis [74]. Genetic
linkage analysis identiﬁes the genomic locus of the miHA by
pair-wise correlation of the miHA phenotype of large CEPH
families with thousands of genetic markers identiﬁed in their
genomes. Alternatively, as miHA are associated with com-
mon polymorphisms within the human population, they can
also be identiﬁed using genetic association studies. This
alternative genetic approach uses the extensive linkage
disequilibrium found within the human genome to efﬁ-
ciently localize the target loci, based on recent advances of
large-scale genotyping technologies and the assets of the
International HapMap Project (www.hapmap.org). Using this
approach, Spaapen et al. [75] identiﬁed a CD19-encoded
miHA, presented by MHC class II molecules by correlating
the miHA phenotypes of 23 CEPH individuals with the SNP
genotypes derived from HapMap. Subsequently, the authors
also identiﬁed the miHA recognized by the 1GF5 CD4þ T cell
clone, isolated from a patient with MM undergoing a strong
GVT response associated with acute GVHD, using another
derivate of forward techniques, a zygosity-genotype corre-
lation analysis with embedded HapMap SNP genotypes from
Figure 1. Schematic representation of a forward immunology method for the identiﬁcation of miHA as tumor targets. Panel (A-1): Identiﬁcation and expansion of T
cell clone with strong GVT/GVHD reactivity. Panel (A-2): The reactive T cell clone is then scanned against a cDNA library with EBV-LCL from CEPH families to identify
the cDNA clone eliciting cytotoxic activity. Genetic linkage analysis is performed on this cDNA clone to identify genes encoding the potential tumor miHA. Panel (B):
Preparation of cDNA library from patient-derived tumor cells or from EBV-LCL from CEPH families. Current methods for the production and expansion of T cell clones
are discussed in more detail in the “Production of bulk T cells as a tool for discovery of TAA” section of this review.
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ern Europe” (known as CEU population) [76].
Whole genome association scans is another forward
approach that allows for high-throughput identiﬁcation of
miHA [77], where third-party EBV-B cell lines selected fortheir coexpression of pertinent HLA molecules, are geno-
typed for more than 1 million SNPs. The miHA are then
identiﬁed by analysis of association between T cell recogni-
tion of these EBV-transformed lymphoblastoid cell lines and
individual SNP genotypes measured in these lines [77,78],
Figure 2. Schematic representation of reversed immunological methods to determine miHA peptides. Steps for determining and validating miHA epitopes eliciting
relevant antitumor T cell activity are depicted in this ﬁgure. A ﬁrst phase of computational prediction determines a number of putative epitopes, which are then
conﬁrmed experimentally for their capacity to induce an in vivo T cell response.
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stromal cells is ruled out to ensure that the T cell clone
exclusively reacts against the hematopoietic (ie, of tumor
origin) compartment [75].
All of these approaches, however, are limited by the
low afﬁnity interaction of the TCR with their speciﬁc
MHC-peptide complex and the technical difﬁculties asso-
ciated with library cloning platforms. Although yet to be
applied to the identiﬁcation of new miHA, Siewert et al.
identiﬁed target antigens of CD8þ T cells using combina-
torial libraries coding for short peptides and a single-cell
detection system with HLA-A*0201 MHC molecules pre-
senting inﬂuenza matrix protein (ﬂu58e66) peptides [79].
The MHC class I cDNA was cotransfected along with a
plasmid-coded combinatorial nonamer peptide library into
COS-7 cells, which allowed antigen processing and pre-
sentation for T cell recognition. For screening, a reporter
T cell hybridoma cell line was cotransfected with the
speciﬁc CD8 TCR a and b chains and the super green
ﬂuorescence protein (sGFP) reporter gene under the tran-
scriptional control of the nuclear factor of activated T cells
enhancer. To identify and isolate an antigenic peptide, a
single nuclear factor of activated T cellseactivated TCR
expressing T cell hybridoma cell that recognized the cor-
rect antigenic peptide expressing COS-7 cell during cocul-
ture was subsequently isolated and the antigenic peptide
plasmid was cloned to determine the precise sequence of
the peptide [79].
Reverse Immunology Methods
An alternative strategy used in the identiﬁcation of tumor
antigens is reverse immunology, in which the prediction of
miHA on hematopoietic cells constitute the starting point
and peptide candidates are subsequently screened for
their capacity to induce a T cellespeciﬁc response [80,81]
(Figure 2). In silico analysis uses prediction algorithms,
such as SYFPEITHI [82] (http://www.syfpeithi.de/), SNP-
derived epitope prediction program [83], which is based
on SYFPEITHI, “BIMAS” (http://bimas.dcrt.nih.gov/molbio/
hla_bind/), and TEPITOPEpan [84,85] (http://www.biokdd.-
fudan.edu.cn/Service/TEPITOPEpan/) to determine peptideswith putative strong binding to HLA-I and HLA-II molecules.
However, because peptide-HLA binding afﬁnity and proteo-
lytic cleavage also play key roles in determining the biolog-
ical feasibility of miHA, the vast majority of T cell responses
detected using this original reverse manner approach were
directed against epitopes that are not naturally processed
and presented [86,87]. Recent technological advances from
the HLA-associated peptidome of hematopoietic cells by
mass spectrometric analysis (HLA peptidomics) SNP data-
bases, MHC-tetramer technology, and multiparametric ﬂow
cytometric analysis were instrumental in the identiﬁcation
of eluted peptide candidates that can undergo HLA-restricted
processing and presentation [80]. Likewise, proteasomal
cleavage and transporter associated with antigen processing
transport efﬁciency has been combined with reverse
computational approaches to optimize the selection of
candidate epitopes [88]. Feldhahn et al. described a different
approach for large-scale detection of tissue-speciﬁc miHA
[89] that uses netMHCpan, a high-throughput computational
method for quantitative predictions of peptide binding to
any HLA-A and -B locus protein of known sequence [90].
Innovative technologies and reduced costs of genomic
sequencing have opened the door for the identiﬁcation of
tumor-associated genes through whole exome sequencing.
Recently, Rosenberg et al. at the National Cancer Institute
developed a screening method to identify mutated gene
products from patients’ tumors and their potential T cell
epitopes that may be recognized by isolated tumor-
inﬁltrated lymphocytes (TILs). Although originally tested in
melanoma, this approach could be extrapolated to other
cancers, including hematological malignancies. Initially,
whole exome sequencing of the tumor was compared to
normal patient’s DNA to identify somatic mutations. Candi-
date mutated T cell epitopes identiﬁed in silico using
netMHCpan were subsequently synthesized in COS-7 cell
lines that were stably transduced to express the appropriate
HLA (as described above), and assayed for their recognition
by TILs. The adoptive transfer of TILs to patients that were
generated after exposure to these identiﬁed dominant
target epitopes mediated signiﬁcant and durable tumor
regression [91].
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DISCOVERY OF TAA
The TCR is a heterodimeric protein, comprising an a and a
b chain, that recognizes antigens presented by MHC mole-
cules. Diversity of the TCR repertoire allows the adaptive
immune system to protect the body against a vast array of
potential pathogens, such as cancer cells and allo-antigens.
These chains are somatically rearranged from individual
gene segments to create millions of different surface re-
ceptors, with the majority of T cells expressing a single
productively rearranged TCR a and b chain allele. The iden-
tiﬁcation of tumor-reactive T cells and their TCR usage
responsible for mounting a signiﬁcant anti-tumor response
is necessary for the discovery of novel tumor antigens. The
generation of a sufﬁcient number of tumor reactive cells is
critical for determining their cognate tumor antigens by
forward immunological approaches and for their adoptive
transfer into patients as immunotherapy.
Unfortunately, the duration of the in vitro selection and
expansion of tumor reactive Tcells as shown in Figure 1 (A-1)
frequently leads to T cell exhaustion, reducing their capacity
to produce cytokines and proliferate to an extent that makes
them unsuitable for use as a tool for antigen discovery. A
more feasible approach to generate sufﬁcient number of
functional T cells for therapeutic transfer has been the pro-
duction of TCR-transgenic T cells restricted to a particular
tumor epitope [92,93]. This approach uses viral transfer of
the genes encoding the TCR a and b chains of identiﬁed
tumor-speciﬁc clones into primary T cells. The advantage of
viral transduction facilitates the generation of large amounts
of antigen-speciﬁc CTLs in several days rather than several
weeks, and thereby bypasses the development of prolifera-
tive senescence and its concomitant decrease in T cell killing
activity.
Vb CDR-3 size spectratyping and TCR deep sequencing,
two techniques aimed at determining the TCR repertoire
usage, have opened the possibility of dissociating GVT and
GVHD responses by identifying allo-reactive and unique
tumor-reactive T cell clones. Our group and others have
extensively used spectratyping to predict Vb families with
in vivo allo-reactive potential in both murine models of BMT
and clinical samples [94-97]. Using this technique, we
identiﬁed those families capable of mounting a strong anti-
tumor response [68,98] that overlapped only moderately
with the induction of GVHD [68]. In particular, our approach
has focused on in vitro mixed lymphocyte cultures, which
expose donor T cells to hematopoietic allo-antigens from
patient-derived peripheral blood mononuclear cells after the
conditioning regimen to identify expanding Tcell clones [94].
We are currently including mixed lymphocyte cultures of
donor T cells stimulated with patient-derived tumor cells
(obtained before conditioning) to distinguish unique donor-
patient antitumor responses (work in progress). Although
spectratype results can be further used to identify the
particular TCR clone that is likely driving the expansion of a
Vb family [99], the feasibility for the rapid identiﬁcation of
tumor or GVHD effector T cells is low because of lengthy
cloning techniques and the random selection of a limited
number of colonies. The advent of next-generation high-
throughput TCR sequencing can generate a sequence of tens
of millions of TCRs from a single sample within a few days.
This methodology uses a multiplex-based PCR method to
identify TCRb chains from genomic DNA, which in turn can
be used to pinpoint tumor-reactive T cells [100-102].
Although the conditions for the identiﬁcation of the TCRachain are currently being optimized, this technology has the
potential to transform the recognition of relevant TCR clones
that can then be engineered into primary T cells for down-
stream immunotherapeutic use [103].
SUMMARY AND FUTURE DIRECTIONS
The development of clinically efﬁcacious cancer vaccines
relies on the identiﬁcation of targetable tumor antigens. In
this review, we summarized some of the major and newest
technological advances currently employed in the discovery
of these antigens, as well as their limitations.We emphasized
the use of these techniques for the recognition of miHA, TAA,
and TSA as tumor targets of hematological malignancies in
the context of allo-BMT. In particular we reviewed forward
methods, which primarily start with identifying the T cell
clone(s) responsible for mediating antitumor responses, as
well as various modalities of reverse immunological ap-
proaches in which prediction of potential antigenic epitopes
are screened for their capability of inducing a physiologically
plausible GVT reaction. As de novo donor-derived immune
cells can be much more readily educated to attack tumor
cells, the use of the posteallo-BMT setting offers a unique
environment to take advantage of cancer vaccines. We also
discussed the techniques for recognition, selection, and
expansion of those tumor-speciﬁc T cell clones that are
necessary to guide the discovery process of tumor antigens.
We believe that the recognition of potential tumor antigens,
currently being used to generate dendritic cell peptide-
loaded vaccines against a particularly relevant miHA, TAA,
or TSA [13,24,104], will be streamlined by the capability to
sequence the TCR of the responding T cell and to generate
bulk quantities of tumor-targeting TCR-transduced T cells for
adoptive immunotherapy. The combination of vaccination
and TCR engineering will likely be used synergistically in
upcoming years to enhance the antitumor response of donor
T cells after transplantation and to provide a durable tumor
remission, if not complete eradication.
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